Left Ventricular Hypertrophy - Pipeline Review, Q2 2011

Date: April 1, 2011
Pages: 33
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L6493B53F95EN
Leaflet:

Download PDF Leaflet

Left Ventricular Hypertrophy - Pipeline Review, Q2 2011
Left Ventricular Hypertrophy - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Left Ventricular Hypertrophy - Pipeline Review, Q2 2011', provides an overview of the Left Ventricular Hypertrophy therapeutic pipeline. This report provides information on the therapeutic development for Left Ventricular Hypertrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Left Ventricular Hypertrophy. 'Left Ventricular Hypertrophy - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Left Ventricular Hypertrophy.
  • A review of the Left Ventricular Hypertrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Left Ventricular Hypertrophy pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Left Ventricular Hypertrophy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Left Ventricular Hypertrophy pipeline depth and focus of Left Ventricular Hypertrophy therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Left Ventricular Hypertrophy Overview
Therapeutics Development
An Overview of Pipeline Products for Left Ventricular Hypertrophy
Left Ventricular Hypertrophy Therapeutics under Development by Companies
Left Ventricular Hypertrophy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Left Ventricular Hypertrophy Therapeutics - Products under Development by Companies
Left Ventricular Hypertrophy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Left Ventricular Hypertrophy Therapeutics Development
Abbott Laboratories
Novartis AG
Left Ventricular Hypertrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ramipril - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Perhexiline - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lisinopril - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Candesartan - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cyclosporine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Aliskiren - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Paricalcitol - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 33

LIST OF TABLES

Number of Products Under Development for Left Ventricular Hypertrophy, Q2 2011
Products under Development for Left Ventricular Hypertrophy – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Abbott Laboratories, 2011
Novartis AG, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011 21

LIST OF FIGURES

Number of Products under Development for Left Ventricular Hypertrophy, Q2 2011 7
Products under Development for Left Ventricular Hypertrophy – Comparative Analysis, Q2 2011 8
Products under Development by Companies, Q2 2011 9
Products under Investigation by Universities/Institutes, Q2 2011 10
Late Stage Products, Q2 2011 12
Mid Clinical Stage Products, Q2 2011 13
Assessment by Monotherapy Products, Q2 2011 17
Assessment by Route of Administration, Q2 2011 18
Assessment by Stage and Route of Administration, Q2 2011 19
Assessment by Molecule Type, Q2 2011 20
Assessment by Stage and Molecule Type, Q2 2011 21

Ask Your Question

Left Ventricular Hypertrophy - Pipeline Review, Q2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: